Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$887.16 USD

887.16
1,970,679

+1.61 (0.18%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWB

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

by Zacks Equity Research

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sanghamitra Saha headshot

Billionaires Bullish on Big Tech: ETFs in Focus

by Sanghamitra Saha

The latest 13-F filings of billionaires indicate that most are still bullish on big techs.

Andrew Rocco headshot

13F Rundown: Tepper, Buffett, Druckenmiller

by Andrew Rocco

Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GSEW

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

by Zacks Equity Research

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.

Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QUS

Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FTCS

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie

by Zacks Equity Research

Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.

Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study

by Zacks Equity Research

Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.

Kinjel Shah headshot

4 Large Drug Stocks Likely to Sail Through Industry Woes

by Kinjel Shah

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

by Zacks Equity Research

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.

Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.

Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla

by Zacks Equity Research

Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.

Sheraz Mian headshot

Earnings Estimates Come Under Pressure

by Sheraz Mian

While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.

Sheraz Mian headshot

Earnings Estimates Come Under Pressure

by Sheraz Mian

While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

by Zacks Equity Research

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Sweta Killa headshot

Eli Lilly Beats on Q3 Earnings: ETFs to Buy

by Sweta Killa

Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.

Company News for Nov 03, 2023

by Zacks Equity Research

Companies In The Article: LLY, SBUX, SHOP, CYBR

Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up

by Zacks Equity Research

Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.